Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2402126
Max Phase: Preclinical
Molecular Formula: C32H33N5O5
Molecular Weight: 567.65
Molecule Type: Small molecule
Associated Items:
ID: ALA2402126
Max Phase: Preclinical
Molecular Formula: C32H33N5O5
Molecular Weight: 567.65
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C=CCn1c(=O)c(C2C(C(=O)OC(C)C)=C(N)N(NC(=O)c3ccncc3)C3=C2C(=O)CCC3)cc2cc(C)ccc21
Standard InChI: InChI=1S/C32H33N5O5/c1-5-15-36-23-10-9-19(4)16-21(23)17-22(31(36)40)26-27-24(7-6-8-25(27)38)37(29(33)28(26)32(41)42-18(2)3)35-30(39)20-11-13-34-14-12-20/h5,9-14,16-18,26H,1,6-8,15,33H2,2-4H3,(H,35,39)
Standard InChI Key: JOSWUCKHDVDNEP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 567.65 | Molecular Weight (Monoisotopic): 567.2482 | AlogP: 3.76 | #Rotatable Bonds: 7 |
Polar Surface Area: 136.62 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 10 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 13.07 | CX Basic pKa: 3.17 | CX LogP: 2.77 | CX LogD: 2.77 |
Aromatic Rings: 3 | Heavy Atoms: 42 | QED Weighted: 0.33 | Np Likeness Score: -1.03 |
1. Jardosh HH, Patel MP.. (2013) Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents., 65 [PMID:23747804] [10.1016/j.ejmech.2013.05.003] |
Source(1):